{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T21:09:49Z","timestamp":1769548189297,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017542","name":"Beijing Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2018YFC2000300"],"award-info":[{"award-number":["2018YFC2000300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","award":["2020YFC2008301"],"award-info":[{"award-number":["2020YFC2008301"]}],"id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.cbi.2022.109799","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T11:25:09Z","timestamp":1641381909000},"page":"109799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Enzymatic activity on valsartan of 38 CYP2C9 variants from the Chinese population"],"prefix":"10.1016","volume":"353","author":[{"given":"Ling-jing","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-chang","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang-yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-ping","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-xin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cbi.2022.109799_bib1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.drudis.2016.09.015","article-title":"Pharmacogenomics of the cytochrome p450 2c family: impacts of amino acid variations on drug metabolism","volume":"22","author":"Isvoran","year":"2017","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.cbi.2022.109799_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/03602530902843483","article-title":"Polymorphism of human cytochrome p450 enzymes and its clinical impact","volume":"41","author":"Zhou","year":"2009","journal-title":"Drug Metab. Rev."},{"issue":"6","key":"10.1016\/j.cbi.2022.109799_bib3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.4103\/0028-3886.105189","article-title":"Association of cyp2c9 polymorphisms with phenytoin toxicity in indian patients","volume":"60","author":"Thakkar","year":"2012","journal-title":"Neurol. India"},{"issue":"7","key":"10.1016\/j.cbi.2022.109799_bib4","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1007\/s12325-019-00976-9","article-title":"Pharmacokinetic drug interactions between amlodipine, valsartan, and rosuvastatin in healthy volunteers","volume":"36","author":"Seong","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.cbi.2022.109799_bib5","doi-asserted-by":"crossref","first-page":"173444","DOI":"10.1016\/j.ejphar.2020.173444","article-title":"Effects of sacubitril\/valsartan in patients with heart failure and chronic kidney disease: a meta-analysis","volume":"884","author":"Kang","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.cbi.2022.109799_bib6","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/00498250500158175","article-title":"Identification of cytochrome p450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin ii receptor antagonist, in human liver microsomes","volume":"35","author":"Nakashima","year":"2005","journal-title":"Xenobiotica; the fate of foreign compounds in biological systems"},{"issue":"4","key":"10.1016\/j.cbi.2022.109799_bib7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF03160932","article-title":"Valsartan ingestions among adults reported to Texas poison control centers, 2000 to 2005","volume":"3","author":"Forrester","year":"2007","journal-title":"J. Med. Toxicol. : official journal of the American College of Medical Toxicology"},{"issue":"1","key":"10.1016\/j.cbi.2022.109799_bib8","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1124\/dmd.112.046292","article-title":"Evaluation of the relationship between sex, polymorphisms in cyp2c8 and cyp2c9, and pharmacokinetics of angiotensin receptor blockers","volume":"41","author":"Cabaleiro","year":"2013","journal-title":"Drug Metab. Dispos.: the biological fate of chemicals"},{"issue":"8","key":"10.1016\/j.cbi.2022.109799_bib9","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/hr.2012.82","article-title":"Pharmacogenomic approaches to study the effects of antihypertensive drugs","volume":"35","author":"Kamide","year":"2012","journal-title":"Hypertens. Res."},{"issue":"11","key":"10.1016\/j.cbi.2022.109799_bib10","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/aps.2013.123","article-title":"In vitro functional characterization of 37 cyp2c9 allelic isoforms found in Chinese han population","volume":"34","author":"Dai","year":"2013","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.cbi.2022.109799_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/tpj.2013.2","article-title":"Cyp2c9 polymorphism analysis in han Chinese populations: building the largest allele frequency database","volume":"14","author":"Dai","year":"2014","journal-title":"Pharmacogenomics J."},{"issue":"11","key":"10.1016\/j.cbi.2022.109799_bib12","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1124\/dmd.114.060244","article-title":"Effects of cytochrome p450 2c9 polymorphism on bosentan metabolism","volume":"42","author":"Chen","year":"2014","journal-title":"Drug Metab. Dispos.: the biological fate of chemicals"},{"key":"10.1016\/j.cbi.2022.109799_bib13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cbi.2016.04.040","article-title":"In vitro metabolism of phenytoin in 36 cyp2c9 variants found in the Chinese population","volume":"253","author":"Chen","year":"2016","journal-title":"Chem. Biol. Interact."},{"issue":"1","key":"10.1016\/j.cbi.2022.109799_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1124\/jpet.116.233635","article-title":"Physiological content and intrinsic activities of 10 cytochrome p450 isoforms in human normal liver microsomes","volume":"358","author":"Zhang","year":"2016","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"1","key":"10.1016\/j.cbi.2022.109799_bib15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0300-483X(03)00247-6","article-title":"Cytochrome p450 enzyme polymorphisms and adverse drug reactions","volume":"192","author":"Pirmohamed","year":"2003","journal-title":"Toxicology"},{"issue":"6947","key":"10.1016\/j.cbi.2022.109799_bib16","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature01862","article-title":"Crystal structure of human cytochrome p450 2c9 with bound warfarin","volume":"424","author":"Williams","year":"2003","journal-title":"Nature"},{"issue":"27","key":"10.1016\/j.cbi.2022.109799_bib17","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.2174\/092986709789057635","article-title":"Substrates, inducers, inhibitors and structure-activity relationships of human cytochrome p450 2c9 and implications in drug development","volume":"16","author":"Zhou","year":"2009","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.cbi.2022.109799_bib18","doi-asserted-by":"crossref","DOI":"10.2174\/1570159X15666171109143654","article-title":"Relevance of cyp2c9 function in valproate therapy","volume":"17","author":"Monostory","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.cbi.2022.109799_bib19","first-page":"51","article-title":"Cyp2c9 polymorphisms in epilepsy: influence on phenytoin treatment","volume":"11","author":"Silvado","year":"2018","journal-title":"Pharmgenomics Pers Med"},{"issue":"4","key":"10.1016\/j.cbi.2022.109799_bib20","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cpt.690","article-title":"Worldwide distribution of cytochrome p450 alleles: a meta-analysis of population-scale sequencing projects","volume":"102","author":"Zhou","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.cbi.2022.109799_bib21","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0090-9556(25)08445-4","article-title":"Relationships between the levels of cytochrome p4502c9 and its prototypic catalytic activities in human liver microsomes","volume":"22","author":"Hall","year":"1994","journal-title":"Drug Metab. Dispos.: the biological fate of chemicals"},{"issue":"3","key":"10.1016\/j.cbi.2022.109799_bib22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3109\/00498254.2013.820007","article-title":"Effect of 36 cyp2c9 variants found in the Chinese population on losartan metabolism in vitro","volume":"44","author":"Wang","year":"2014","journal-title":"Xenobiotica; the fate of foreign compounds in biological systems"},{"issue":"5","key":"10.1016\/j.cbi.2022.109799_bib23","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1124\/mol.107.036178","article-title":"Polymorphic variants of cyp2c9: mechanisms involved in reduced catalytic activity","volume":"72","author":"Wei","year":"2007","journal-title":"Mol. Pharmacol."},{"issue":"41","key":"10.1016\/j.cbi.2022.109799_bib24","doi-asserted-by":"crossref","first-page":"5476","DOI":"10.1021\/acs.biochem.7b00795","article-title":"Structural basis of single-nucleotide polymorphisms in cytochrome p450 2c9","volume":"56","author":"Maekawa","year":"2017","journal-title":"Biochemistry"},{"issue":"21","key":"10.1016\/j.cbi.2022.109799_bib25","doi-asserted-by":"crossref","first-page":"8639","DOI":"10.1021\/bi00447a054","article-title":"Structural and functional analysis of nadph-cytochrome p-450 reductase from human liver: complete sequence of human enzyme and nadph-binding sites","volume":"28","author":"Haniu","year":"1989","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.cbi.2022.109799_bib26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s13318-014-0245-2","article-title":"The role of cyp2c9 genetic polymorphism in carvedilol o-desmethylation in vitro","volume":"41","author":"Pan","year":"2016","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.cbi.2022.109799_bib27","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.2147\/DDDT.S268796","article-title":"Functional measurement of cyp2c9 and cyp3a4 allelic polymorphism on sildenafil metabolism","volume":"14","author":"Tang","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"issue":"10","key":"10.1016\/j.cbi.2022.109799_bib28","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.biochi.2006.05.001","article-title":"On the human cyp2c9*13 variant activity reduction: a molecular dynamics simulation and docking study","volume":"88","author":"Zhou","year":"2006","journal-title":"Biochimie"},{"issue":"6","key":"10.1016\/j.cbi.2022.109799_bib29","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/FPC.0b013e328344c340","article-title":"Characterization of a novel cyp2c9 gene mutation and structural bioinformatic protein analysis in a warfarin hypersensitive patient","volume":"21","author":"Ciccacci","year":"2011","journal-title":"Pharmacogenetics Genom."},{"issue":"7","key":"10.1016\/j.cbi.2022.109799_bib30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/01.fpc.0000215069.14095.c6","article-title":"Four novel defective alleles and comprehensive haplotype analysis of cyp2c9 in Japanese","volume":"16","author":"Maekawa","year":"2006","journal-title":"Pharmacogenetics Genom."},{"issue":"3","key":"10.1016\/j.cbi.2022.109799_bib31","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1124\/jpet.105.091181","article-title":"Functional characterization of novel allelic variants of cyp2c9 recently discovered in southeast asians","volume":"315","author":"DeLozier","year":"2005","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"7","key":"10.1016\/j.cbi.2022.109799_bib32","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1080\/004982598239236","article-title":"The cyp2 family: models, mutants and interactions","volume":"28","author":"Lewis","year":"1998","journal-title":"Xenobiotica; the fate of foreign compounds in biological systems"},{"issue":"9","key":"10.1016\/j.cbi.2022.109799_bib33","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1124\/dmd.109.027003","article-title":"Substrate-dependent functional alterations of seven cyp2c9 variants found in Japanese subjects","volume":"37","author":"Maekawa","year":"2009","journal-title":"Drug Metab. Dispos.: the biological fate of chemicals"},{"issue":"1","key":"10.1016\/j.cbi.2022.109799_bib34","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2133\/dmpk.DMPK-11-RV-090","article-title":"In vitro assessment of the allelic variants of cytochrome p450","volume":"27","author":"Hiratsuka","year":"2012","journal-title":"Drug Metabol. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.cbi.2022.109799_bib35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/tpj.2013.22","article-title":"Functional characterization of 32 cyp2c9 allelic variants","volume":"14","author":"Niinuma","year":"2014","journal-title":"Pharmacogenomics J."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279722000047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279722000047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T19:49:00Z","timestamp":1762112940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279722000047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":35,"alternative-id":["S0009279722000047"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2022.109799","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enzymatic activity on valsartan of 38 CYP2C9 variants from the Chinese population","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2022.109799","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109799"}}